India Leadership Conclave 2017 nomination process journey began in the first quarter of the calendar year in 2017 from Jan-March to find out the best talents, innovators, reformers, social entrepreneurs, public administrators in the top categories through a very standard fair & independent way of bringing top six names to the final list of voting. The internal team of experts at Network 7 Media Group, the flagship media property of Indian Affairs looked at the all round progress of the individuals/companies & consultations were made with various associations of india & trade bodies. Final selections were made by public from the recommendations of the top industry associations & chamber of commerce. Upon much consideration, research & detailed analysis, nominees were found based on a robust process that involved considerable comprehensive mechanism that Network 7 Media Group do years after years.
Very importantly, India Leadership Conclave’s mantra is very simple & clear. We dont follow a fixed set of rules of traditional theories of selecting a nominee in the final six list either based on seniority, age or celebrity status. We go by our research, experts advise & bring to light those talent & innovators who never got noticed in mainstream media or recognized. When they see their names in the big six final list, they feel proud, for us, that is the winning moments after relentlessly following & chasing for finding the credible name!
Here are the final six nominees at the 8th Annual India Leadership Conclave 2017
India’ Most Innovative Pharmaceutical Company of the Year 2017
1. Sun Pharmaceutical Industries Limited.(91)
2. Cipla Limited.(92)
3. Cadila Healthcare Ltd.(93)
4. Mankind Pharma Limited.(94)
5. Alkem Laboratories Limited.(95)
6. Intas Pharmaceuticals Limited.(96)
Under the leadership of Narendra Modi, the government has shown it understands the need to develop the country’s innovative life sciences sector.The Government is due to announce a major reform of intellectual property laws, which it sees as crucial for developing modern, high tech industries. Meanwhile, the Make in India campaign and the last Budget created a number of tax incentives and R&D initiatives aimed at increasing private and public sector research investment. If the pharmaceutical sector is to help propel India towards the next stage of economic development, it needs to be generating much more value, and that means creating medicines instead of just manufacturing copies of what’s invented elsewhere.
The US pharmaceutical industry, largely comprised of innovative, R&D-focused companies, generates a direct output of $4,61,000 per employee in comparison to $1,49,000 on average for other sectors. In Europe, the pharmaceutical industry contributed an international trade surplus of $54 billion. It is no wonder western governments view these industries as major economic assets.
India is now becoming a serious player in vaccine innovation, for instance, with Hyderabad’s Bharat Biotech’s innovative H1N1influenza and rotavirus vaccines and the two anti-malaria vaccines being jointly developed by Ranbaxy and Bharat Biotech. Domestic companies also promise much in active therapeutic proteins, protein and antibody production, and fabrication of diagnostic protein chips.Patients are also benefiting from changes in the Indian industry. Bengaluru’s Biocon is close to releasing an insulin product that can be consumed orally. If successful, it could spell the end of the daily injections regime for around 387 million people with diabetes worldwide, including 67 million in India.